Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study  Pablo Aschner, Bipin Sethi, Fernando Gomez-Peralta, Wolfgang Landgraf, Virginie Loizeau, Marie-Paule Dain, Valerie Pilorget, Abdurrahman Comlekci  Journal of Diabetes and Its Complications  Volume 29, Issue 6, Pages 838-845 (August 2015) DOI: 10.1016/j.jdiacomp.2015.04.003 Copyright © 2015 The Authors Terms and Conditions

Fig. 1 Seven-point BG profile of overall groups at baseline and study end. Abbreviation: ETD, end of treatment difference; EOT, end of treatment; GLA, glargine; GLU, glulisine; PRE, premixed insulin. Journal of Diabetes and Its Complications 2015 29, 838-845DOI: (10.1016/j.jdiacomp.2015.04.003) Copyright © 2015 The Authors Terms and Conditions

Fig. 2 Cumulative rates of overall (A, B) and nocturnal (C, D) symptomatic hypoglycemia confirmed with BG ≤3.1 (A, C) or BG ≤3.9mmol/L (B, D): safety population. Abbreviations: BG, blood glucose; GLA, glargine; GLU, glulisine; PRE, premixed insulin; RR, relative risk. Journal of Diabetes and Its Complications 2015 29, 838-845DOI: (10.1016/j.jdiacomp.2015.04.003) Copyright © 2015 The Authors Terms and Conditions

Fig. 3 Estimated rates of symptomatic hypoglycemia versus HbA1c at study end: overall (A, B) and nocturnal (C, D) symptomatic hypoglycemia confirmed by BG ≤3.1mmol/L (A, C) or BG ≤3.9mmol/L (B, D). Abbreviations: BG, blood glucose; GLA, glargine; PRE, premixed insulin. Journal of Diabetes and Its Complications 2015 29, 838-845DOI: (10.1016/j.jdiacomp.2015.04.003) Copyright © 2015 The Authors Terms and Conditions